Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced
April 21, 2008
Genzyme Pompe Program Update—April 2008
We would like to take this opportunity to provide an important update related to Myozyme (alglucosidase alfa) manufacturing in the
January 15, 2008
January 2008 US Myozyme Supply Update
In April 2007, Genzyme implemented measures to manage the limited supply of Myozyme® (alglucosidase alfa) in the United States in
December 13, 2007
Genzyme Study of Myozyme® for Late-Onset Pompe Patients
CAMBRIDGE, Mass. – Genzyme Corp. (Nasdaq: GENZ) announced today that its Late Onset Treatment Study (LOTS) of Myozyme® (alglucosidase alfa)